Noclaud (Cilostazol)

Cilostazol, the active ingredient in Noclaud, is a phosphodiesterase 3 inhibitor presented as an oral dosage form for oral use. It treats intermittent claudication and peripheral arterial disease in adult patients. GNH USA supplies Noclaud as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Cilostazol is indicated for conditions affecting peripheral circulation and walking ability. - Intermittent claudication: improves pain‑free walking distance in patients with peripheral arterial disease. - Peripheral arterial disease: reduces limb ischemic symptoms and enhances functional capacity. - Symptomatic peripheral vascular disease: alleviates leg pain and improves exercise tolerance.

Cilostazol may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Dizziness: sensation of light‑headedness, especially on standing. - Nausea: occasional upset stomach or feeling of queasiness.

Serious or Rare Side Effects: - Thrombocytopenia: significant reduction in platelet count requiring monitoring. - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Rhabdomyolysis: muscle breakdown with potential kidney injury.

Cilostazol requires careful consideration of patient‑specific factors before prescribing. - Heart failure: avoid use in patients with symptomatic heart failure. - Bleeding risk: monitor patients with a history of bleeding or on anticoagulants. - Hepatic impairment: use with caution in moderate to severe liver disease. - Renal impairment: dose adjustment may be needed in severe renal dysfunction. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at room temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Cilostazol can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase cilostazol levels and toxicity. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Other antiplatelet agents (e.g., clopidogrel, aspirin): additive antithrombotic effect increasing hemorrhage risk.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., omeprazole, fluvoxamine): may modestly raise cilostazol concentrations. - Antihypertensive drugs (e.g., beta‑blockers, ACE inhibitors): potential additive blood‑pressure lowering effect.